Edgar Petru - Gynecology

Author Information

Dr. Edgar Petru is affiliated with the Department of Obstetrics and Gynecology at the Medical University of Graz in Graz, Austria. He is a distinguished researcher and has contributed significantly to the field of gynecology and oncology.

Research Contributions

Dr. Edgar Petru has made substantial contributions to gynecology and oncology, focusing on breast cancer, ovarian cancer, and chemotherapy-induced nausea and vomiting. His recent work includes studies on antiemetic guideline compliance, treatment algorithms in HER2+ metastatic breast cancer, and the prognostic significance of driver gene mutations in micro-invasive cervical cancers. Dr. Petru has also investigated the efficacy of various chemotherapy regimens and the predictive value of ctDNA persistence in breast cancer patients. His research has been instrumental in advancing treatment protocols and improving patient outcomes.

Aliases

Dr. Edgar Petru is also known by the following aliases: E Petru, E. Petru, and Edga Petru.

Publication and Citation Metrics

Metric	Value
Citation Count	4929
H-index	36
Paper Count	302

Publications:

Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO).

DOI: 10.1016/j.ejca.2022.01.028

Year: 2022

Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

DOI: 10.1007/s00508-021-01987-9

Year: 2022

Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.

DOI: 10.1016/j.ygyno.2022.01.020

Year: 2022

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)

DOI: 10.1177/17588359211042301

Year: 2021

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial

DOI: 10.1016/s0090-8258(21)00695-8

Year: 2021

203P Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer

DOI: 10.1016/j.annonc.2021.08.485

Year: 2021

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34

DOI: 10.1038/s41416-021-01284-2

Year: 2021

383 ”Quick” Laparoscopy for suspected advanced ovarian cancer

DOI: 10.1136/ijgc-2021-esgo.394

Year: 2021

EPV203/#449 ‘Quick’ laparoscopy for suspected advanced ovarian cancer

DOI: 10.1136/ijgc-2021-igcs.274

Year: 2021

Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response.

DOI: 10.1158/1078-0432.CCR-21-3231

Year: 2021

Why is Postoperative Care Important?

What Happens After the Check-Up?

How is Engagement Determined?

Why is Immunosuppressive Therapy Used in Gynecology?

What Are the Unique Challenges for Primiparous Women?

How can regular screenings reduce risks?

How does body weight affect the risk of gynecological cancers?

What Role Does Epigenetics Play?

What are Hormonal Fluctuations?

What Does a Medical Laboratory Technician Do in Gynecology?

Partnered Content Networks

Relevant Topics